{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:28:48Z","timestamp":1767896928892,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jpba.2023.115885","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:46:56Z","timestamp":1701125216000},"page":"115885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Simultaneous determination of tipiracil, trifluridine and its metabolite 5-trifluoromethyluracil in human plasma using segmented polarity LC-MS\/MS: A fully validated assay with clinical application"],"prefix":"10.1016","volume":"239","author":[{"given":"Rong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115885_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.canlet.2021.09.034","article-title":"Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America","volume":"522","author":"Li","year":"2021","journal-title":"Cancer Lett."},{"issue":"10207","key":"10.1016\/j.jpba.2023.115885_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jpba.2023.115885_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.jpba.2023.115885_bib4","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-15-2783","article-title":"TAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapies","volume":"22","author":"van der Velden","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.jpba.2023.115885_bib5","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 2","key":"10.1016\/j.jpba.2023.115885_bib6","article-title":"How we treat metastatic colorectal cancer","volume":"4","author":"De Falco","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jpba.2023.115885_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2016.05.015","article-title":"Review on TAS-102 development and its use for metastatic colorectal cancer","volume":"104","author":"Mota","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.jpba.2023.115885_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1758834015603313","article-title":"Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies","volume":"7","author":"Peters","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"9","key":"10.1016\/j.jpba.2023.115885_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","article-title":"TAS-102, a novel antitumor agent: a review of the mechanism of action","volume":"41","author":"Lenz","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.jpba.2023.115885_bib10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2032-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharm."},{"issue":"3","key":"10.1016\/j.jpba.2023.115885_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/17512433.2016.1133285","article-title":"A novel antimetabolite: TAS-102 for metastatic colorectal cancer","volume":"9","author":"Miyamoto","year":"2016","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.jpba.2023.115885_bib12","first-page":"e531","article-title":"Real-world treatment patterns among patients with colorectal cancer treated with trifluridine\/tipiracil and regorafenib","volume":"17","author":"Patel","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"5","key":"10.1016\/j.jpba.2023.115885_bib13","first-page":"2135","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts","volume":"33","author":"Tsukihara","year":"2015","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.jpba.2023.115885_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-015-2805-9","article-title":"Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse","volume":"76","author":"Yamashita","year":"2015","journal-title":"Cancer Chemother. Pharm."},{"issue":"3","key":"10.1016\/j.jpba.2023.115885_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-016-2965-2","article-title":"Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry","volume":"77","author":"Lee","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.jpba.2023.115885_bib16","first-page":"21","article-title":"Pharmacokinetics, safety, and preliminary efficacy of oral trifluridine\/tipiracil in chinese patients with solid tumors: a phase 1b, open-label study","volume":"12","author":"Wang","year":"2020","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.jpba.2023.115885_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00280-021-04277-3","article-title":"Phase II study of trifluridine\/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers","volume":"88","author":"Takahashi","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.jpba.2023.115885_bib18","unstructured":"I.C.H. Harmonised guideline: Bioanalytical method validation and study sample analysis, M10, 2022, (Accessed 3 November, 2023). https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf."},{"issue":"16","key":"10.1016\/j.jpba.2023.115885_bib19","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1021\/acs.analchem.9b01872","article-title":"What color is your method? Adaptation of the RGB additive color model to analytical method evaluation","volume":"91","author":"Nowak","year":"2019","journal-title":"Anal. Chem."},{"issue":"8","key":"10.1016\/j.jpba.2023.115885_bib20","first-page":"1075","article-title":"New bioanalytical microemulsion Electrokinetic chromatography method for the simultaneous determination of Trifluridine with its metabolites and Tipiracil in rat plasma: application to pharmacokinetic studies, Saudi","volume":"27","author":"Hefnawy","year":"2019","journal-title":"Pharm. J."},{"issue":"3","key":"10.1016\/j.jpba.2023.115885_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031092","article-title":"Developed and validated capillary isotachophoresis method for the rapid determining organic acids in children's saliva","volume":"28","author":"Dobrowolska-Iwanek","year":"2023","journal-title":"Molecules"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:29:41Z","timestamp":1760002181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523006544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":21,"alternative-id":["S0731708523006544"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115885","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of tipiracil, trifluridine and its metabolite 5-trifluoromethyluracil in human plasma using segmented polarity LC-MS\/MS: A fully validated assay with clinical application","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115885"}}